| Indications for IVIG in rheumatic diseases B Mulhearn, IN Bruce Rheumatology 54 (3), 383-391, 2015 | 100 | 2015 |
| Autoantibodies in connective tissue disease B Mulhearn, SL Tansley, NJ McHugh Best Practice & Research Clinical Rheumatology 34 (1), 101462, 2020 | 22 | 2020 |
| Using the immunophenotype to predict response to biologic drugs in rheumatoid arthritis B Mulhearn, A Barton, S Viatte Journal of Personalized Medicine 9 (4), 46, 2019 | 21 | 2019 |
| What rheumatologists need to know about innate lymphocytes MA Exley, GC Tsokos, KHG Mills, D Elewaut, B Mulhearn Nature Reviews Rheumatology 12 (11), 658-668, 2016 | 11 | 2016 |
| A commercial anti-TIF1γ ELISA is superior to line and dot blot and should be considered as part of routine myositis-specific antibody testing B Mulhearn, D Li, F McMorrow, H Lu, NJ McHugh, SL Tansley Frontiers in Immunology 13, 804037, 2022 | 10 | 2022 |
| Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary … SL Barratt, HH Adamali, C Cotton, B Mulhearn, H Iftikhar, JD Pauling, ... BMJ Open Respiratory Research 8 (1), e000829, 2021 | 7 | 2021 |
| The use of ELISA is comparable to immunoprecipitation in the detection of selected myositis-specific autoantibodies in a European population A Loganathan, F McMorrow, H Lu, D Li, B Mulhearn, NJ McHugh, ... Frontiers in Immunology 13, 975939, 2022 | 4 | 2022 |
| Automated clustering reveals CD4+ T cell subset imbalances in rheumatoid arthritis B Mulhearn, L Marshall, M Sutcliffe, SK Hannes, C Fonseka, T Hussell, ... Frontiers in Immunology 14, 1094872, 2023 | 2 | 2023 |
| Rituximab fails to treat giant cell arteritis in a patient with ACPA-positive rheumatoid arthritis B Mulhearn, E Cooper, S Knights Rheumatology Advances in Practice 5 (1), rkab020, 2021 | 2 | 2021 |
| Relapse after cessation of weekly tocilizumab for giant cell arteritis: a multicentre service evaluation in England V Quick, M Abusalameh, S Ahmed, H Alkoky, M Bukhari, S Carter, ... Rheumatology, kead604, 2023 | 1 | 2023 |
| OP0281 EXCESS GIANT CELL ARTERITIS CASES ARE ASSOCIATED WITH PEAKS IN COVID-19 PREVALENCE B Mulhearn, J Ellis, S Skeoch, J Pauling, S Tansley Annals of the Rheumatic Diseases 80 (Suppl 1), 170-170, 2021 | 1 | 2021 |
| Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database J Ellis, A McGrogan, N McHugh, B Mulhearn, E Korendowych, J Pauling, ... ARTHRITIS & RHEUMATOLOGY 75, 258-259, 2023 | | 2023 |
| Incidence of giant cell arteritis is associated with COVID-19 prevalence: A population-level retrospective study B Mulhearn, J Ellis, S Skeoch, J Pauling, S Tansley Heliyon 9 (7), 2023 | | 2023 |
| POS0726 RITUXIMAB VERSUS CYCLOPHOSPHAMIDE FOR ANCA-ASSOCIATED VASCULITIS: A COST ANALYSIS E Amor, B Mulhearn, W Tillett, C Cavill, S Tansley Annals of the Rheumatic Diseases 82 (Suppl 1), 651-651, 2023 | | 2023 |
| Correspondence on ‘Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported … B Mulhearn Annals of the rheumatic diseases 82 (5), e115, 2023 | | 2023 |
| Monocular Vision Loss in a Patient With Earache and Night Sweats S Schimansky, G Cross, B Mulhearn JAMA ophthalmology 141 (4), 396-397, 2023 | | 2023 |
| P208 PET-CT scanning of GCA patients: the additive role of opportunistic screening for cardiovascular disease in a high-risk population B Mulhearn, J Ellis, R Foley, S Gunawardana, R Wickramarachchi, ... Rheumatology 62 (Supplement_2), kead104. 249, 2023 | | 2023 |
| P110 Challenges of meeting NICE guidance for rheumatoid arthritis in the modern era: a service audit H Cooney, J Ellis, B Mulhearn, A Allard Rheumatology 62 (Supplement_2), kead104. 151, 2023 | | 2023 |
| E070 How well is the mental health of rheumatoid arthritis patients assessed in the routine rheumatology clinic? H Cooney, J Ellis, B Mulhearn, A Allard Rheumatology 62 (Supplement_2), kead104. 319, 2023 | | 2023 |
| A Commercial Anti-TIF1g ELISA Is Superior to Line and Dot Blot and Should Be Considered as Part of Routine Myositis-Specific Antibody Testing B Mulhearn, D Li, F McMorrow, H Lu, NJ McHugh, SL Tansley Autoimmune Myositis: From Immunological to Rheumatological Aspects, 2022 | | 2022 |
Sarah TansleyVerified email at bath.ac.uk
